KRAS and non-small cell lung carcinoma: As previously mentioned, KRAS-mutant NSCLC patients are expected to benefit from immune checkpoint inhibitors (ICIs) [136], and this has been demonstrated in particular in KRAS c.34G > T (p.G12C) mutant individuals [137,138].